US equities
|
MU
$1,088.00
▲+4.06%
NVDA
$237.47
▼-0.74%
SNDK
$1,692.42
▲+1.92%
SPCX
$167.60
▼-2.51%
AMD
$645.86
▼-0.55%
AAPL
$336.67
▲+0.91%
TSLA
$377.81
▼-0.75%
META
$721.31
▼-2.38%
MU
$1,088.00
▲+4.06%
NVDA
$237.47
▼-0.74%
SNDK
$1,692.42
▲+1.92%
SPCX
$167.60
▼-2.51%
AMD
$645.86
▼-0.55%
AAPL
$336.67
▲+0.91%
TSLA
$377.81
▼-0.75%
META
$721.31
▼-2.38%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Articles published by 2seventy bio
2seventy bio to Participate in the 2024 Morgan Stanley Global Healthcare Conference
August 29, 2024
From
2seventy bio
Via
Business Wire
Tickers
TSVT
2seventy bio and JW Therapeutics Announce Intent To Expand Strategic Partnership to Accelerate the Research and Development of T Cell-based Immunotherapies and Autoimmune Therapies
September 12, 2023
From
2seventy bio
Via
Business Wire
Tickers
TSVT
2seventy bio to Participate in 2023 Wedbush PacGrow Healthcare Conference
August 01, 2023
From
2seventy bio
Via
Business Wire
Tickers
TSVT
2seventy bio Presents Late-Breaking Results for SC-DARIC33, an Investigational CD33-Targeting CAR T in Pediatric and Young Adults with Relapsed or Refractory Acute Myeloid Leukemia
May 19, 2023
From
2seventy bio
Via
Business Wire
Tickers
TSVT
2seventy bio to Present New Preclinical and Clinical Data from Broad Portfolio of Investigational Cell Therapies at the ASGCT 26th Annual Meeting
May 02, 2023
From
2seventy bio
Via
Business Wire
Tickers
TSVT
2seventy bio and Novo Nordisk Collaboration Delivers Key Proof of Concept Data, Triggering $15 Million Preclinical Milestone in In Vivo Gene Editing Hemophilia A Program
May 01, 2023
From
2seventy bio
Via
Business Wire
Tickers
TSVT